Cholangiocarcinoma

Stefania Mosconi, Giordano D. Beretta, Roberto Labianca, Maria G. Zampino, Gemma Gatta, Volker Heinemann

Research output: Contribution to journalArticle

104 Citations (Scopus)

Abstract

Cholangiocarcinoma is an uncommon adenocarcinoma with poor prognosis. Although the 1-year survival has increased over time, the 5-year survival has not shown any significant change (less than 5%). Cure can only be expected from surgical resection of early stage tumours but most patients initially present with advanced disease. Cancer cachexia, liver failure, and recurrent sepsis due to biliary obstruction are among the main causes of mortality. Patients' prognosis is strongly related to radical surgery and complete resection is the most effective therapy; the location within the biliary tree (proximal versus distal) has no impact on survival when a complete resection is achieved despite the fact the rate of resectability is up to 70% in case of distal cancer and 15-20% for high bile ducts tumours. Prognosis of cholangiocarcinoma remains poor even with aggressive surgical therapy because of the high incidence of local or regional recurrence and distant metastasis. Based on these data many questions need an answer: is there a role for adjuvant chemotherapy or radiotherapy? Neoadjuvant treatments provide best results? There is a standard therapy in unresectable or metastatic cholangiocarcinoma? This report tries to answer to frequently asked questions that the readers are faced with their patients every day (from diagnostic procedures to palliative treatment) and tries to suggest useful information for their professional practice.

Original languageEnglish
Pages (from-to)259-270
Number of pages12
JournalCritical Reviews in Oncology/Hematology
Volume69
Issue number3
DOIs
Publication statusPublished - Mar 2009

Fingerprint

Cholangiocarcinoma
Survival
Neoplasms
Cachexia
Adjuvant Radiotherapy
Neoadjuvant Therapy
Professional Practice
Liver Failure
Biliary Tract
Adjuvant Chemotherapy
Liver Neoplasms
Bile Ducts
Palliative Care
Sepsis
Adenocarcinoma
Therapeutics
Neoplasm Metastasis
Recurrence
Mortality
Incidence

Keywords

  • Chemotherapy
  • Cholangiocarcinoma
  • Liver transplantation
  • Radiation
  • Surgical resection

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Hematology
  • Oncology

Cite this

Cholangiocarcinoma. / Mosconi, Stefania; Beretta, Giordano D.; Labianca, Roberto; Zampino, Maria G.; Gatta, Gemma; Heinemann, Volker.

In: Critical Reviews in Oncology/Hematology, Vol. 69, No. 3, 03.2009, p. 259-270.

Research output: Contribution to journalArticle

Mosconi, S, Beretta, GD, Labianca, R, Zampino, MG, Gatta, G & Heinemann, V 2009, 'Cholangiocarcinoma', Critical Reviews in Oncology/Hematology, vol. 69, no. 3, pp. 259-270. https://doi.org/10.1016/j.critrevonc.2008.09.008
Mosconi, Stefania ; Beretta, Giordano D. ; Labianca, Roberto ; Zampino, Maria G. ; Gatta, Gemma ; Heinemann, Volker. / Cholangiocarcinoma. In: Critical Reviews in Oncology/Hematology. 2009 ; Vol. 69, No. 3. pp. 259-270.
@article{1f26feb7cd81438192346597daa91644,
title = "Cholangiocarcinoma",
abstract = "Cholangiocarcinoma is an uncommon adenocarcinoma with poor prognosis. Although the 1-year survival has increased over time, the 5-year survival has not shown any significant change (less than 5{\%}). Cure can only be expected from surgical resection of early stage tumours but most patients initially present with advanced disease. Cancer cachexia, liver failure, and recurrent sepsis due to biliary obstruction are among the main causes of mortality. Patients' prognosis is strongly related to radical surgery and complete resection is the most effective therapy; the location within the biliary tree (proximal versus distal) has no impact on survival when a complete resection is achieved despite the fact the rate of resectability is up to 70{\%} in case of distal cancer and 15-20{\%} for high bile ducts tumours. Prognosis of cholangiocarcinoma remains poor even with aggressive surgical therapy because of the high incidence of local or regional recurrence and distant metastasis. Based on these data many questions need an answer: is there a role for adjuvant chemotherapy or radiotherapy? Neoadjuvant treatments provide best results? There is a standard therapy in unresectable or metastatic cholangiocarcinoma? This report tries to answer to frequently asked questions that the readers are faced with their patients every day (from diagnostic procedures to palliative treatment) and tries to suggest useful information for their professional practice.",
keywords = "Chemotherapy, Cholangiocarcinoma, Liver transplantation, Radiation, Surgical resection",
author = "Stefania Mosconi and Beretta, {Giordano D.} and Roberto Labianca and Zampino, {Maria G.} and Gemma Gatta and Volker Heinemann",
year = "2009",
month = "3",
doi = "10.1016/j.critrevonc.2008.09.008",
language = "English",
volume = "69",
pages = "259--270",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Cholangiocarcinoma

AU - Mosconi, Stefania

AU - Beretta, Giordano D.

AU - Labianca, Roberto

AU - Zampino, Maria G.

AU - Gatta, Gemma

AU - Heinemann, Volker

PY - 2009/3

Y1 - 2009/3

N2 - Cholangiocarcinoma is an uncommon adenocarcinoma with poor prognosis. Although the 1-year survival has increased over time, the 5-year survival has not shown any significant change (less than 5%). Cure can only be expected from surgical resection of early stage tumours but most patients initially present with advanced disease. Cancer cachexia, liver failure, and recurrent sepsis due to biliary obstruction are among the main causes of mortality. Patients' prognosis is strongly related to radical surgery and complete resection is the most effective therapy; the location within the biliary tree (proximal versus distal) has no impact on survival when a complete resection is achieved despite the fact the rate of resectability is up to 70% in case of distal cancer and 15-20% for high bile ducts tumours. Prognosis of cholangiocarcinoma remains poor even with aggressive surgical therapy because of the high incidence of local or regional recurrence and distant metastasis. Based on these data many questions need an answer: is there a role for adjuvant chemotherapy or radiotherapy? Neoadjuvant treatments provide best results? There is a standard therapy in unresectable or metastatic cholangiocarcinoma? This report tries to answer to frequently asked questions that the readers are faced with their patients every day (from diagnostic procedures to palliative treatment) and tries to suggest useful information for their professional practice.

AB - Cholangiocarcinoma is an uncommon adenocarcinoma with poor prognosis. Although the 1-year survival has increased over time, the 5-year survival has not shown any significant change (less than 5%). Cure can only be expected from surgical resection of early stage tumours but most patients initially present with advanced disease. Cancer cachexia, liver failure, and recurrent sepsis due to biliary obstruction are among the main causes of mortality. Patients' prognosis is strongly related to radical surgery and complete resection is the most effective therapy; the location within the biliary tree (proximal versus distal) has no impact on survival when a complete resection is achieved despite the fact the rate of resectability is up to 70% in case of distal cancer and 15-20% for high bile ducts tumours. Prognosis of cholangiocarcinoma remains poor even with aggressive surgical therapy because of the high incidence of local or regional recurrence and distant metastasis. Based on these data many questions need an answer: is there a role for adjuvant chemotherapy or radiotherapy? Neoadjuvant treatments provide best results? There is a standard therapy in unresectable or metastatic cholangiocarcinoma? This report tries to answer to frequently asked questions that the readers are faced with their patients every day (from diagnostic procedures to palliative treatment) and tries to suggest useful information for their professional practice.

KW - Chemotherapy

KW - Cholangiocarcinoma

KW - Liver transplantation

KW - Radiation

KW - Surgical resection

UR - http://www.scopus.com/inward/record.url?scp=63749123217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63749123217&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2008.09.008

DO - 10.1016/j.critrevonc.2008.09.008

M3 - Article

VL - 69

SP - 259

EP - 270

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 3

ER -